Clinical TrialsThe Phase 1b LOTIS-7 study of Zynlonta + Columvi showed highly competitive efficacy data, which strengthens the company's clinical portfolio.
Financial PerformanceADC Therapeutics reported a net loss of $0.29 per share, which was narrower than the previously estimated net loss of $0.41 per share.
Financial ResourcesThe company's balance sheet resources are expected to provide an operational runway through multiple data catalysts, supporting future growth.